BridgeMD
Biomarkers of the locus coeruleus nucleus: links with early tau pathology, cognition and AD risk. LocusTau
EU CTIS ID: 2023-507668-38-00
What this study is testing
The present project has the following objectives: 1) to relate different biomarkers of LC function measured in vivo with AD risk and future AD occurrence, in order to evaluate their relevance for earliest AD diagnosis,
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Age ≥ 60 years.
- - Participant in the INSPIRE-T cohort.
- - Normal cognitive assessment.
- - MMSE score ≥ 27 out of 30 (Mini-Mental State Examination).
- - Normal visual abilities (in corrected or uncorrected vision).
- - Normal motor skills.
You likely can't join if
- Subjects with a contraindication to MRI exam (presence of a pacemaker or a cardiac defibrillator; implanted devices activated by an electrical, magnetic, or mechanical system; hemostatic clips for intracerebral aneurysms or carotid arteries; orthopedic implants; claustrophobia).
- - Subjects with a known allergic reaction to the PET radiopharmaceutical ([18F] Flortaucipir) or any of its excipients
- - Subjects with an ophthalmological pathology making oculometric measurements difficult (glaucoma, age-related macular degeneration, non-operated cataracts).
- - Persons protected by law (adults under guardianship or safeguard of justice).
- Subjects participating in another research protocol and under exclusion delay.
- - Subjects with a neurodegenerative condition or a history of cerebral ischemia
See the full eligibility criteria
- - Age ≥ 60 years.
- - Participant in the INSPIRE-T cohort.
- - Normal cognitive assessment.
- - MMSE score ≥ 27 out of 30 (Mini-Mental State Examination).
- - Normal visual abilities (in corrected or uncorrected vision).
- - Normal motor skills.
- - Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).
- - Person affiliated to or benefiting from a social security scheme.
- For participants in the ApoE4 group only: presence of the ApoE4 allele (phenotyping of ApoE protein isoforms carried out as part of the INSPIRE project).
- Subjects with a contraindication to MRI exam (presence of a pacemaker or a cardiac defibrillator; implanted devices activated by an electrical, magnetic, or mechanical system; hemostatic clips for intracerebral aneurysms or carotid arteries; orthopedic implants; claustrophobia).
- - Subjects with a known allergic reaction to the PET radiopharmaceutical ([18F] Flortaucipir) or any of its excipients
- - Subjects with an ophthalmological pathology making oculometric measurements difficult (glaucoma, age-related macular degeneration, non-operated cataracts).
- - Persons protected by law (adults under guardianship or safeguard of justice).
- Subjects participating in another research protocol and under exclusion delay.
- - Subjects with a neurodegenerative condition or a history of cerebral ischemia
- Subjects with a psychiatric disorder and a PHQ-9 score > 10 or under treatment with NRI
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.